Clinical Research Helps Heart Encounter Patients
/* 468x60, */
Kimberly Skelding, M.D., FACC, FAHA, FSCAI, associate, Interventional Cardiology at Geisinger Medical Center, employer of Cardiovascular Genomics and Cardiovascular Proof at the Sigfried and Janet Weis Centre for Research and director of Women's Affection and Vascular Health Program, is one of 17 doctors in the country who is implanting the Watchman LAA slogan in patients with nonvalvular atrial fibrillation (AF) as atom of a nationwide clinical trial.
The device is designed for AF patients who are on the medication Coumadin (warfarin) to prevent a stroke. AF is a condition that causes an abnormal feelings rhythm, and is the influential cause of stroke.
Coumadin had formerly been the only protocol for treating AF, but it comes with its own issues. As a blood thinner, patients are at risk for severe bleeding. Also, the patient faces the inconvenience of blood draws every few weeks to scanner its effects on the body and dosage changes.
The Watchman device, which is implanted through a minimally invasive procedure into the heart where clots could form, testament authority AF while allowing patients to living without the medication and its risks. Most patients are typically taken off the medication 45 days after the device is implanted.
"Patients no longer have to worry approximately falling, getting cuts or having surgery," said Dr. Skelding, lead investigator of the Watchman trial. "Prior to this device, patients were facing a duration on Coumadin and a career of worry."
The Cheer and Narcotic Government advisory panel has recommended the device be approved as an alternative to Coumadin for the prevention of stroke in AF patients.
"All the patients I've implanted with the Watchman LAA device are doing de facto fit and are excited about its possibilities," said Skelding.
About Geisinger Health System
Founded in 1915, Geisinger Health System is one of the nations largest integrated health services organizations. Serving more than 2.6 million residents throughout central and northeastern Pennsylvania, the physician-led party is a nationally recognized big wheel in the manipulate of electronic health records, patient access and engagement in their healthcare, and in medical education for the next generation. Geisinger is comprised of three medical center campuses, a 740-member group practice, a not-for-profit health insurance business and research that extends across our enormous system- all committed to creating fresh models for scientific discovery, quality patient care, and fortuitous clinical outcomes. Geisinger's Weis Center, Center for Health Test and Center for Clinical Studies append basic science, population-based and clinical trials research, complemented by collaborative relationships with top academic centers. Geisinger Ventures, the system's for income entrepreneurial arm, seeks and promotes opportunities to rush the delivery of medical innovation to extras patients.
Source: Geisinger Health Development
View drug enlightenment on Warfarin Sodium tablets.
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
patients, encounter patients, patients clinical, af patients, patients typically, patients source, patients living, patients kimberly, patients risk, patients medication